Evidence map›Paper›PMID 26749143›Full record

ArticleHead & neck2016

Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials.

Hisham Mehanna, Natalie Franklin, Natalie Compton, Max Robinson, Ned Powell, Nigel Biswas-Baldwin, Vindh Paleri, Andrew Hartley, Lydia Fresco, Hoda Al-Booz and 7 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Head & neck, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03532737 (Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03532737 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer

TypeinterventionalSponsorKuwait Cancer Control CenterRan2018 to 2025Enrolled50ConditionsLocally Advanced Head and Neck CancerArmsPembrolizumab
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Global epidemiologic patterns of oropharyngeal cancer incidence trends.Journal of the National Cancer Institute · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 15 institutions in 2 countries.

Hisham MehannaInstitute of Head and Neck Studies and Education (InHANSE), School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Natalie FranklinRoche Products Ltd, Shire Park, Welwyn Garden City, United Kingdom.
Natalie ComptonPPD, Granta Park, Great Abington, Cambridge, United Kingdom.
Max RobinsonCentre for Oral Health Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom.
Ned PowellHPV Oncology Group, Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Nigel Biswas-BaldwinGSK, Uxbridge, Middlesex, United Kingdom.
Vindh PaleriDepartment of Otolaryngology-Head and Neck Surgery, Newcastle upon Tyne Hospitals, NHS Trust, and Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
Andrew HartleyHall-Edwards Radiotherapy Research Group, Old Queen Elizabeth Hospital, Birmingham, United Kingdom.
Lydia FrescoDepartment of Oncology, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom.
Hoda Al-BoozBristol Haematology and Oncology Centre, Bristol, United Kingdom.
Elizabeth JunorEdinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom.
Iman El-HariryDepartment of Clinical Research, Synta Pharmaceuticals Corp, Lexington, Massachusetts.
Sally RobertsSchool of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Kevin HarringtonThe Institute of Cancer Research, London, United Kingdom.
K Kian AngDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Janet DunnWarwick Clinical Trials Unit, University of Warwick, Gibbet Hill Campus, Coventry, United Kingdom.
Ciaran WoodmanSchool of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Newcastle University · GBUniversity of Birmingham · GBAt Bristol · GBCancer Research UK Clinical Trials Unit · GBCardiff University · GBEdinburgh Cancer Research · GBEdwards (United Kingdom) · GBGranta Design (United Kingdom) · GBInstitute of Cancer Research · GBMiddlesex University · GBRoche (United Kingdom) · GBSynta Pharmaceuticals (United States) · USThe University of Texas MD Anderson Cancer Center · USUniversity Hospitals Coventry and Warwickshire NHS Trust · GBUniversity of Warwick · GB

Funding

Cancer Research UK 13407Medical Research Council MR/N005872/1
6 · The paper itself

Abstract

backgroundThere are variations in the proportions of head and neck cancers caused by the human papillomavirus (HPV) between countries and regions. It is unclear if these are true variations or due to different study designs and assays.

methodsWe tested formalin-fixed paraffin-embedded diagnostic biopsies for p16 immunohistochemistry and HPV-DNA (by polymerase chain reaction [PCR] and in situ hybridization [ISH]) using validated protocols on samples from 801 patients with head and neck cancer recruited prospectively between 2006 and 2011 in 4 randomized controlled trials (RCTs).

resultsTwenty-one percent of patients (170 of 801) showed both HPV-DNA and p16-positivity, detected almost exclusively in oropharyngeal cancer (55%; 15 of 302); and only 1% of the patients (5 of 499) with nonoropharyngeal cancer were HPV positive. HPV-positive oropharyngeal cancer differed between Western and Eastern Europe (37%, 155 of 422 vs 6%, 8 of 144; p < .0001) and between Western Europe and Asia (37% vs 2%; 4 of 217; p < .0001). Other independent determinants of HPV positivity were tumor site and smoking.

conclusionThis is the first study to establish geographic variability as an independent risk factor in HPV-positive oropharyngeal cancer prevalence, with higher prevalence in Western Europe. © 2016 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck 38: E1863-E1869, 2016.

Indexed as

Carcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16DNA, ViralEuropeGeographyHumansImmunohistochemistryOropharyngeal NeoplasmsPapillomaviridaePapillomavirus InfectionsRandomized Controlled Trials as TopicCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DNA, Viralhead and neck cancerhuman papillomavirusoropharynxprevalencesquamous cell carcinoma

Identifiers

PMID26749143
PMCPMC4869674
OpenAlexW2223310350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.